NEW YORK, May 21, 2026, 07:16 EDT
Neurogene Inc. shares barely moved in premarket trading on Nasdaq Thursday. Investors looked past new disclosures and kept their eyes on the upcoming clinical milestone for NGN-401, the lead gene therapy for Rett syndrome.
The stock finished Wednesday at $26.95, gaining 7 cents, or 0.3%. It traded in a range from $26.50 to $28.08. Broader markets rallied too, with the Nasdaq Composite adding 1.5% and the Russell 2000 up 2.6% on Wednesday.
U.S. equity markets hadn’t started their regular session at the time. Nasdaq lists normal trading from 9:30 a.m. to 4 p.m. Eastern. According to Nasdaq’s 2026 holiday calendar, the next holiday is Memorial Day on May 25. That doesn’t fall on Thursday.
Neurogene said about 90% of patients have now been dosed in Embolden, a registrational trial aiming to back an approval filing. The biotech still plans to finish dosing in the second quarter. Updated interim Phase 1/2 safety and efficacy data are expected by mid-2026.
Neurogene Founder and CEO Rachel McMinn said the company is seeing growing physician and caregiver interest in NGN-401, and said the team is “laser-focused on completing dosing.” Neurogene said there have been no reports of HLH — hemophagocytic lymphohistiocytosis, a dangerous immune response — among patients dosed with NGN-401 at 1E15 vg, as of May 11. The company said the treatment has been generally well tolerated at that dose.
Neurogene says its cash pile should last into early 2028. The biotech ended March with $243.2 million in cash, cash equivalents and short-term investments. Neurogene posted a first-quarter net loss of $30.9 million, up from $22.6 million the year before.
No fresh company filings have come in to update the story. Neurogene’s investor page shows its latest quarterly and current reports were both filed May 12. The company last reported ownership-related filings in early May.
Analysts remain mostly bullish, but with the company’s small market cap, the stock could move a lot. S&P Global data from StockAnalysis shows a “Strong Buy” consensus. The average price target over 12 months is $80, with estimates spanning from $46 to $180. StockAnalysis
Competition in Rett syndrome is heating up. Taysha Gene Therapies has started dosing in the Phase 3 part of its REVEAL trial for TSHA-102, its gene therapy candidate. Acadia Pharmaceuticals’ Daybue, which is not a gene therapy, is still the main commercial player in Rett, after reporting $101 million in net sales for the first quarter.
The risks are clear. Neurogene’s latest quarterly filing notes that AAV gene therapies can cause serious side effects, manufacturing issues, trial delays, or regulatory problems. The company also says if the FDA shifts its stance on trial design, approvals could be set back or blocked. For investors, any safety issue, delayed results, or stricter regulators could push the stock down fast.
NGNE has turned into a data-timing play for now. Investors are watching for more than just the next earnings report. The key is whether Neurogene wraps up Embolden dosing and produces midyear data that is solid enough to keep the Rett program going.
